Vermillion (NASDAQ:VRML) issued its earnings results on Thursday, March 28th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04), Morningstar.com reports. Vermillion had a negative return on equity of 150.85% and a negative net margin of 372.45%. The firm had revenue of $0.92 million for the quarter.
Shares of NASDAQ:VRML traded down $0.02 during midday trading on Friday, reaching $1.32. 46,336 shares of the company traded hands, compared to its average volume of 161,965. The company has a current ratio of 3.64, a quick ratio of 3.61 and a debt-to-equity ratio of 0.18. Vermillion has a 12 month low of $0.27 and a 12 month high of $1.57.
In other news, Director David Schreiber sold 30,000 shares of Vermillion stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $1.00, for a total value of $30,000.00. Following the sale, the director now directly owns 137,405 shares of the company’s stock, valued at $137,405. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.25% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Vermillion (VRML) Issues Quarterly Earnings Results” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/21/vermillion-vrml-releases-quarterly-earnings-results-meets-estimates.html.
Vermillion Company Profile
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Further Reading: What is Call Option Volume?
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.